The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

This website is intended for healthcare professionals only

Banner BG

RAS-PI3K⍺ Signaling

See how Bayer is investigating RAS-PI3K⍺ signaling across the oncology pipeline

Explore the investigational compounds, tumor types, and clinical trials associated with this area of research.

RAS-PI3K⍺ Signaling

  • Rat sarcoma (RAS) proteins are membrane-bound guanosine triphosphatases that can cause cancers by activating the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) signaling pathways1

  • PI3Ks are a family of lipid kinases regulating a variety of cellular processes2

    • Specifically, somatic mutations in PIK3CA, a gene that encodes one of the catalytic subunits of PI3K, induce the aberrant activation of protein kinase B (Akt) signaling and promote tumor growth1-3

    • Thus, RAS-PI3Kα signaling supports tumor growth by stimulating proliferation and preventing apoptosis1

  • Bayer is currently investigating a potential inhibitor of RAS-PI3Kα signaling for the treatment of advanced solid tumors4

Tumor Types

Gastrointestinal cancer (colorectal, pancreatic)
Lung cancer
Solid tumors

Related Compound

RAS-PI3Kα inhibitor (BAY 3674171)

Bayer’s Oncology Pipeline Brochure

Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.

Download BrochurePDF (1.45 MB)

The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.